ARVN Arvinas Inc

Price (delayed)

$29.95

Market cap

$1.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.31

Enterprise value

$1.51B

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing ...

Highlights
Arvinas's revenue has soared by 145% YoY and by 10% from the previous quarter
The gross profit has soared by 145% YoY and by 10% from the previous quarter
The debt rose by 10% year-on-year but it has declined by 7% since the previous quarter
The company's net income fell by 48% YoY and by 12% QoQ
The EPS has contracted by 39% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of ARVN
Market
Shares outstanding
53.27M
Market cap
$1.6B
Enterprise value
$1.51B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.82
Price to sales (P/S)
12.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.52
Earnings
Revenue
$131.4M
EBIT
-$261.6M
EBITDA
-$253.4M
Free cash flow
-$280.3M
Per share
EPS
-$5.31
Free cash flow per share
-$5.27
Book value per share
$10.61
Revenue per share
$2.47
TBVPS
$23.85
Balance sheet
Total assets
$1.27B
Total liabilities
$703.9M
Debt
$5.5M
Equity
$564.9M
Working capital
$945.1M
Liquidity
Debt to equity
0.01
Current ratio
4.2
Quick ratio
4.13
Net debt/EBITDA
0.32
Margins
EBITDA margin
-192.8%
Gross margin
100%
Net margin
-215%
Operating margin
-200.3%
Efficiency
Return on assets
-20.5%
Return on equity
-43.8%
Return on invested capital
-25.4%
Return on capital employed
-26.9%
Return on sales
-199.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARVN stock price

How has the Arvinas stock price performed over time
Intraday
0.57%
1 week
10.8%
1 month
-15.25%
1 year
-54.38%
YTD
-12.45%
QTD
-12.45%

Financial performance

How have Arvinas's revenue and profit performed over time
Revenue
$131.4M
Gross profit
$131.4M
Operating income
-$263.2M
Net income
-$282.5M
Gross margin
100%
Net margin
-215%
Arvinas's revenue has soared by 145% YoY and by 10% from the previous quarter
The gross profit has soared by 145% YoY and by 10% from the previous quarter
The company's net income fell by 48% YoY and by 12% QoQ
Arvinas's operating margin has increased by 43% YoY

Growth

What is Arvinas's growth rate over time

Valuation

What is Arvinas stock price valuation
P/E
N/A
P/B
2.82
P/S
12.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.52
The EPS has contracted by 39% YoY and by 11% from the previous quarter
The stock's price to book (P/B) is 45% less than its 5-year quarterly average of 5.1 and 26% less than its last 4 quarters average of 3.8
The company's equity fell by 28% YoY and by 9% QoQ
Arvinas's revenue has soared by 145% YoY and by 10% from the previous quarter
The P/S is 78% below the 5-year quarterly average of 54.6 and 54% below the last 4 quarters average of 26.5

Efficiency

How efficient is Arvinas business performance
ARVN's return on equity has dropped by 60% year-on-year and by 21% since the previous quarter
The ROS has grown by 44% YoY and by 2.3% from the previous quarter
ARVN's return on assets is down by 21% year-on-year and by 18% since the previous quarter
The company's return on invested capital fell by 16% QoQ and by 8% YoY

Dividends

What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARVN.

Financial health

How did Arvinas financials performed over time
ARVN's total assets is 80% more than its total liabilities
The quick ratio has declined by 30% year-on-year and by 21% since the previous quarter
ARVN's current ratio is down by 29% YoY and by 21% QoQ
The debt is 99% smaller than the equity
The company's equity fell by 28% YoY and by 9% QoQ
The debt rose by 10% year-on-year but it has declined by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.